Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report January-June 2018: Yet another quarter of strong growth and good results

· The organic growth rate continues to increase based on good demand at all clinics and amounts to 17 percent · Continued focus on developing the Nordic business through controlled expansion and several small improvements · New collaboration at International and Vårdsamverkan increases GHP’s competitiveness · Strategic initiatives in the digital offer, within Vårdsamverkan, will give a long term positive effect on the result Second quarter 2018 · Sales revenues increased to SEK 287.6 million (249.6) · Organic growth amounted to 17.0 percent (-4.5) · EBITDA amounted to

Cxense ASA : End of quarter recurring revenue update

Oslo, Norway - 13 July 2018 - Cxense ASA (OSE: CXENSE) today announced that it in Q2 2018 signed 25 new contracts with Quarterly Recurring Revenue (QRR) effect of USD 316 thousand for the company's core software offering, the Data Management Platform with Intelligent Personalization. 60% of the new QRR came from new customers and the remaining from upsells to existing customers. With on average 11.5 effective sales quotas during Q2, sales efficiency was up 2% compared to Q1 2018. Full QRR effect from contracts notified to be terminated (churn) in Q2 2018 was USD -199 thousand for the

Interim report Q2 of Cloetta AB April – June 2018

Improved EBIT and growth within branded packaged products• Net sales for the quarter increased by 4.1 per cent to SEK 1,472m (1,414) including a positive impact from foreign exchange rates of 3.6 per cent. • Operating profit amounted to SEK 155m (90). Profit for the period amounted to SEK 97m (–329). Operating profit, adjusted for items affecting comparability, amounted to SEK 145m (115). • Cash flow from operating activities amounted to SEK 119m (117). • Net debt/EBITDA ratio was 2.77x (2.77). Please find enclosed the full report. The interim report will be presented at a

Interim Report January-June 2018

Strong earnings trend with good growth”ÅF delivers strong second quarter results and its best half-year results ever, which lays the groundwork for continued profitable growth,” said Jonas Gustavsson, President and CEO. Second quarter 2018 · Net sales amounted to SEK 3,608 million (3,231) · EBITA excl items affecting comparability, was SEK 366 million (302) · EBITA margin, excl items affecting comparability, was 10.2 percent (9.4) · EBITA totalled SEK 366 million (282) · EBITA margin was 10.2 percent (8.7) · EBIT (operating profit) was SEK 353 million (273) · Basic

Heimstaden acquires first property in Germany

Heimstaden has today signed an agreement to buy its first property in Berlin, Germany.The acquisition comes after a period of market study and analysis of potential objects for sale. The property is located in the district of Berlin-Spandau, close to Spandau city centre, in the west of Berlin in a typical residential area. The property benefits from good connections to both motorway network and public transport links. The property comprises 27 831 m2 split over 10 buildings with 484 flats and 50 parking places. Purchase price amounts to m€ 66. The property is sold by a Berlin based

Interim report January – June 2018

SOME STABILIZATION OF THE HOUSING MARKET IN STOCKHOLM - STABLE DEVELOPMENT ON OTHER MARKETSRevenue decreased to SEK 8,179m (8,644) and operating profit decreased to SEK 1,032m (1,188). The operating margin was 12.6 percent (13.7) Profit before tax decreased to SEK 997m (1,430) 1). Profit after tax was SEK 776m (1,177) 1) Return on equity for the past twelve months decreased to 30.7 percent (41.6) 1). Earnings per share for the first six months were SEK 11.10 (16.50) 1) Consolidated cash flow including net investment in properties was SEK –222m (1,294) The number of sold

Vattenfall, Novozymes and Novo Nordisk sign a long term Power Purchase Agreement from Denmark’s largest offshore wind park, Kriegers Flak

Production of insulin and enzymes is to be based on renewable energy from Denmark’s largest offshore wind farm, Kriegers Flak in the Baltic Sea. This is the result of a new long-term deal between global healthcare company Novo Nordisk, bio innovator Novozymes and the energy company Vattenfall.Novo Nordisk and Novozymes will source their power consumption from Vattenfall and its offshore wind farm Kriegers Flak, which is being developed in the Baltic Sea. The deal will cover approximately a fifth of the farm’s production. Kriegers Flak is scheduled to be in full operation by the end of

Q-FREE – NOTICE OF EXTRAORDINARY GENERAL MEETING

(This notice is a translation of the Norwegian notice of the Extraordinary General meeting. If any deviation between the two versions, the Norwegian version shall prevail.) Notice is hereby given that an Extraordinary General meeting in Q-Free ASA will be held on Friday 17 August 2018 at 09.00 hrs at the Company's office in Parkveien 55, Oslo. The notice and papers, together with the notice of attendance and proxy form, are sent to all shareholders with known addresses registered in the Norwegian Security Depository (VPS) as of 10 July 2018. In accordance with the Company's

Interim report January-June 2018

Interim report January-June 2018           Strong order growth “Mycronic performs well, as we simultaneously invest in continued growth. We delivered particularly strong order growth during the year’s second quarter, and we have a good base of planned deliveries from our order backlog to reach net sales at a level of SEK 3.5 billion, excluding acquisitions, for the year. During the first half-year, we executed 3 planned deliveries of mask writers, compared to 7 deliveries last year. We have also taken another important step in line with our strategy through the acquisition of American MRSI

Interim Report April-June 2018

“General knowledge and understanding of Oncopeptides and our clinical strategy has greatly increased during the spring”Summary of Q2 Financial overview April 1 – June 30 2018 ·  Net sales amounted to 0.0 (0.0) MSEK ·  Loss for the period was 143.1 (loss: 67.3) MSEK ·  Loss per share, before and after dilution, was 3.27 (loss: 1.69) SEK ·  On June 30 cash and cash equivalents amounted to 568.2 (535.1) MSEK Significant events during the period April 1 to June 30 2018 ·  First patient started treatment with Ygalo® in the Phase I/II study ANCHOR ·  A Clinical

Half year report for 1 January – 30 June 2018

NEW STRATEGY FOCUSING ON THREE INDEPENDENT COMPANIESSECOND QUARTER[1] · Net sales increased to SEK 807.0 (805.3) million · The gross margin increased by 0.9 percentage points to 25.0 (24.1) percent · Operating income before depreciation, amortization and impairment amounted to SEK 7.7 (27.5) million · Operating income amounted to SEK -10.3 (9.0) million · Profit after tax including discontinued operations amounted to SEK -91.7 (-5.3) million including tax and interest expenses of SEK 70 million attributable to CDON Alandia year 2012 · Basic and diluted earnings per share

Kesko’s sales in June

The sales of Kesko Group’s continuing operations in June 2018 totalled €912.6 million, and were at the previous year's level in comparable terms. The reported sales from continuing operations decreased by 4.2%, and were impacted by divestments. The number of wholesale selling days was one less than the year before. "Kesko's sales were at the previous year’s level in comparable terms in June. In the second quarter the sales grew in all segments in comparable terms,” says Kesko's President and CEO Mikko Helander. Sales in the grocery trade totalled €448.8 million in June, an increase of

Kværner ASA: Kvaerner awarded additional scope at Njord A

13 July 2018 - Equinor has awarded Kvaerner an additional scope at Njord A to enable the platform to receive oil from the Fenja field. The additional scope has an estimated value of approximately NOK 500 million. At 17 March 2017, Kvaerner signed a contract with Equinor for the complete upgrading of the Njord A floating production platform. This contract includes the full upgrading of hull and topside, a scope which will enable the contract to produce oil and gas for decades ahead. In addition to production from the Njord field, the platform will also receive oil and gas from the

Interim Report for Duni AB (publ) 1 January – 30 June 2018

Margins under pressure from strongly increasing pulp prices1 April – 30 June · Net sales amounted to SEK 1,197 m (1,101). Adjusted for exchange rate movements, net sales increased by 4.0%. Organic growth for the quarter was 1.9%.  · Earnings per share after dilution amounted to SEK 1.39 (1.54). · Previously announced price increases under implementation and new price increases adopted to compensate for the strong rise in raw materials and energy costs. 1 January – 30 June · Net sales amounted to SEK 2,277 m (2,106). Adjusted for exchange rate movements, net sales

Storebrand Livsforsikring AS: 2Q Interim report 2018

Storebrand Livsforsikring AS is a wholly owned subsidiary of the listed company Storebrand ASA. For information about the Storebrand Group's 2Q 2018 result and Balance sheet statement, please refer to the Storebrand Group 2Q 2018 interim report. Storebrand Livsforsikring AS Group's interim report for 2Q 2018 is attached. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Arjo acquires ReNu Medical – a green medical reprocessor of single use medical devices

Arjo, a market-leading supplier of medical devices and solutions, today signed an agreement to acquire ReNu Medical Inc. ReNu Medical is a privately owned US company specialising in green reprocessing for single use non-invasive medical devices. The acquisition is expected to have a marginal positive effect on netsales, gross margin and earnings per share in 2018. “The acquisition of ReNu Medical strengthens our offering in compression therapy, such as DVT* prevention, and we also see excellent opportunities for launching this offering in markets outside the US. The acquisition

Interim report January – June 2018

Quote from Therese Hillman, Group CEO”During the quarter, we came up with a plan and started taking action in several areas to strengthen our customer offering, cut lead times, and free up resources for new commercial projects. These changes are necessary for us to reassert our strong market position in online casino. I look forward to a busy autumn, focused on the turnaround of NetEnt, with improved efficiency and many new products and growth initiatives that all have players and customers in focus.” Second quarter 2018 · Revenues for the second quarter amounted to SEK 437 (413)

Storebrand ASA, 2Q Interim Result 2018: Strong Group result and continued growth

· Group result of NOK 812m for the 2nd quarter and NOK 1,743m year to date  · Good growth in savings volume  · Result positively affected by strong insurance results  · Increased Solvency II ratio to 167% - Growth in Savings, combined with a strong insurance results and good cost control, contributes to the strong result in the 2nd quarter 2018. We are pleased with the results, says Group CEO Odd Arild Grefstad. Good growth in operating profit The operating profit for the second quarter was NOK 645m, an increase of 16% compared to the second quarter last year. Income grew

INTERIM REPORT JANUARY-JUNE 2018 NORDAX BANK AB

JANUARY-JUNE 2018 (Numbers compared with January-June 2017) · Operating profit was 254 MSEK (251) · Credit losses amounted to -174 MSEK (-95) corresponding to a credit loss level of 2.5% (1.5%) · Total operating expenses amounted to -263 MSEK (-235)  Nordax Bank AB (publ) is a fully owned subsidiary to Nordax Group AB (publ). For more information, please contact Andreas Frid, Head of Investor Relations, Nordax Tel: +46 705 29 08 00 E-mail: ir@nordax.se This information is information that Nordax Bank AB (publ) is obliged to make public pursuant to the EU Market

Kojamo Plc: Exercise of over-allotment option and discontinuation of the stabilization period

Kojamo Plc                               Stock Exchange Release                      13 July 2018, at 08:30 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, JAPAN, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Exercise of over-allotment option and discontinuation of the stabilization period With reference to the offering circular published by Kojamo Plc ("Kojamo"

Elisa’s Half-Year Financial Report January–June 2018

ELISA CORPORATION HALF-YEAR FINANCIAL REPORT RELEASE 13 JULY 2018 AT 8:30 AM Second quarter 2018 · Revenue amounted to EUR 458 million (445) · Comparable EBITDA was EUR 157 million (151) and EBIT EUR 98 million (92) · Reported EBITDA was EUR 160 million (148) and EBIT EUR 101 million (88) · Comparable earnings per share were EUR 0.47 (0.44), reported EPS EUR 0.49 (0.70) · Cash flow after investments was EUR 81 million (76) · Mobile post-paid voice ARPU was EUR 20.4 (20.4 in previous quarter) · Mobile post-paid voice churn was 17.4 per cent (19.2 in previous

AKERBP: Key information relating to the cash dividend to be paid by Aker BP ASA

Dividend amount: USD 0.3124 per share (NOK 2.53 per share) Declared currency: USD Last day of trading including right: 31 July 2018 Ex-date: 1 August 2018 Record date: 2 August 2018 Payment date: 9 August 2018 Date of approval: 12 July 2018 As per the updated loan agreement in the DETNOR02 bond loan (ISIN: NO 001068414.5), clause 12.4, bondholders have an option to put bonds at 107% of the dividend distribution amount. A distribution event notice will be sent to bondholders on the dividend payment date.

Changes in Orkla's Group Executive Board

Orkla will make changes in its Group Executive Board as of 1 October. The intention is to strengthen the Group's strategic priority areas. As from 1 October 2018, the Group Executive Board will consist of the following members: Peter A. Ruzicka will continue as President and CEO. Jens B. Staff will continue as EVP, CFO. Karl Otto Tveter, (today: Chief of Group Functions and Group Director Legal Affairs): EVP, Strategy, Development & New Growth Areas. Atle Vidar Nagel Johansen, (today: EVP, CEO Orkla Foods): EVP, Supply Chain. Ann-Beth Freuchen, (today: EVP, CEO Orkla

There are no items matching the current filter
There are no more items matching the current filter
Back to top